Sintilimab
Sintilimab is an antibody pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
558 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 10 | 88 | 18 | 1 | 36 | 146 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 10 | 46 | 10 | 1 | 35 | 95 |
| Non-small-cell lung carcinoma | D002289 | — | — | 11 | 39 | 14 | 1 | 5 | 68 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 10 | 44 | 11 | 1 | 5 | 68 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 10 | 54 | 5 | 1 | 5 | 66 |
| Lymphoma | D008223 | — | C85.9 | 1 | 19 | 1 | 1 | — | 21 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 6 | 1 | 1 | 1 | 9 |
| Hodgkin disease | D006689 | — | C81 | 1 | 2 | 1 | 1 | 1 | 5 |
| Triple negative breast neoplasms | D064726 | — | — | — | 3 | — | 1 | — | 4 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 9 | 45 | 9 | — | 26 | 82 |
| Neoplasms | D009369 | — | C80 | 23 | 30 | 3 | — | 6 | 52 |
| Colorectal neoplasms | D015179 | — | — | 6 | 28 | 4 | — | 9 | 43 |
| Squamous cell carcinoma | D002294 | — | — | 2 | 28 | 7 | — | 4 | 40 |
| Adenocarcinoma | D000230 | — | — | 4 | 27 | 3 | — | 5 | 36 |
| Esophageal squamous cell carcinoma | D000077277 | — | — | 2 | 21 | 7 | — | 4 | 33 |
| Immunotherapy | D007167 | — | — | 4 | 20 | 1 | — | 5 | 27 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 2 | 18 | 1 | — | — | 20 |
| Esophageal neoplasms | D004938 | — | C15 | 4 | 14 | 1 | — | 1 | 18 |
| Rectal neoplasms | D012004 | — | — | 3 | 15 | 1 | — | — | 16 |
Show 15 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| T-cell lymphoma peripheral | D016411 | — | — | — | 13 | — | — | — | 13 |
| T-cell lymphoma | D016399 | — | — | — | 13 | — | — | — | 13 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | 11 | — | — | — | 12 |
| Cholangiocarcinoma | D018281 | — | C22.1 | 1 | 9 | — | — | 2 | 11 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 7 | — | — | 1 | 8 |
| Drug therapy | D004358 | — | — | — | 6 | — | — | 1 | 7 |
| Biliary tract neoplasms | D001661 | — | C24.9 | 1 | 6 | — | — | 1 | 7 |
| Uterine cervical neoplasms | D002583 | HP_0030159 | — | 2 | 6 | — | — | 1 | 7 |
| Healthy volunteers/patients | — | — | — | 4 | 4 | — | — | — | 6 |
| Chemoradiotherapy | D059248 | — | — | 1 | 5 | — | — | 1 | 6 |
Show 54 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteosarcoma | D012516 | — | — | 1 | — | — | — | — | 1 |
| Adenocarcinoma of lung | D000077192 | — | — | 1 | — | — | — | — | 1 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver diseases | D008107 | HP_0002910 | K70-K77 | — | — | — | — | 2 | 2 |
| Hepatitis b | D006509 | — | — | — | — | — | — | 2 | 2 |
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | — | — | — | — | 2 | 2 |
| Hepatitis | D006505 | HP_0012115 | K75.9 | — | — | — | — | 2 | 2 |
| Chronic hepatitis | D006521 | — | K73.9 | — | — | — | — | 2 | 2 |
| Catheter ablation | D017115 | — | — | — | — | — | — | 2 | 2 |
| Female genital neoplasms | D005833 | — | — | — | — | — | — | 1 | 1 |
| Abdominal neoplasms | D000008 | — | — | — | — | — | — | 1 | 1 |
| Meningioma | D008579 | EFO_0003098 | D32.9 | — | — | — | — | 1 | 1 |
| Venous thrombosis | D020246 | HP_0004936 | I82.40 | — | — | — | — | 1 | 1 |
Show 9 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Sintilimab |
| INN | sintilimab |
| Description | Sintilimab, sold under the brand Tyvyt among others, is a medication used to treat Hodgkin's disease, and has been approved in China.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 2072873-06-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297829 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB15765 |
| UNII ID | 8FU7FQ8UPK (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,584 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
358 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use